Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of recombinant human coagulation factor VIIa for on-demand treatment of bleeding in hemophilia with inhibitors
ChiCTR2500099911Phase 3Completed
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor VIIa in hemophilia A and hemophilia B (HB), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of all bleeding events successfully stopped after treatment. Started Apr 2025; status: completed.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on ChiCTR2500099911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099911.